Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anthracyclines: selected new developments.

M Binaschi1, M Bigioni, A Cipollone

  • 1Menarini Ricerche, via Tito Speri, 10, 00040 Pomezia, Rome, Italy. mbinaschi@menarini-ricerche.it

Current Medicinal Chemistry. Anti-Cancer Agents
|April 8, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Challenges in diagnosing and managing non-cavitated occlusal caries lesions. A Literature overview and a report of a case.

La Clinica terapeutica·2020
Same author

Probing the N=32 Shell Closure below the Magic Proton Number Z=20: Mass Measurements of the Exotic Isotopes ^{52,53}K.

Physical review letters·2015
Same author

Limited asymmetry dependence of correlations from single nucleon transfer.

Physical review letters·2014
Same author

Isotopic chains around oxygen from evolved chiral two- and three-nucleon interactions.

Physical review letters·2013
Same author

Novel anthracycline oligosaccharides: influence of chemical modifications of the carbohydrate moiety on biological activity.

Bioorganic & medicinal chemistry·2002
Same author

Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue.

British journal of pharmacology·2001
Same journal

Selenium derivatives as cancer preventive agents.

Current medicinal chemistry. Anti-cancer agents·2005
Same journal

Lycopene: a review of its potential as an anticancer agent.

Current medicinal chemistry. Anti-cancer agents·2005
Same journal

Sulfo-quinovosyl-acyl-glycerol (SQAG), a eukaryotic DNA polymerase inhibitor and anti-cancer agent.

Current medicinal chemistry. Anti-cancer agents·2005
Same journal

Current drug therapy for prostate cancer: an overview.

Current medicinal chemistry. Anti-cancer agents·2005
Same journal

Lanthanides as anticancer agents.

Current medicinal chemistry. Anti-cancer agents·2005
Same journal

Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy.

Current medicinal chemistry. Anti-cancer agents·2005
See all related articles

Anthracycline antibiotics target DNA topoisomerase II in cancer chemotherapy. Research focuses on developing new analogues with improved efficacy and reduced side effects by understanding structure-activity relationships.

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Oncology

Background:

  • Anthracycline antibiotics are crucial in cancer treatment.
  • Improving their therapeutic index is a key research goal.
  • DNA topoisomerase II is the primary cellular target for anthracyclines like doxorubicin.

Purpose of the Study:

  • To review the development of anthracycline analogues.
  • To explore structure-function relationships for enhanced drug design.
  • To discuss new synthetic strategies and drug delivery systems.

Main Methods:

  • Investigating the mechanism of action of anthracyclines on DNA topoisomerase II.
  • Developing molecular models of drug-receptor interactions.
  • Establishing structure-activity relationships for analogue design.

Related Experiment Videos

Main Results:

  • Anthracyclines stabilize a topoisomerase II-DNA intermediate, leading to DNA strand breaks.
  • Drug intercalation is essential but not sufficient for activity.
  • Specific chemical modifications significantly enhance activity and alter DNA cleavage sequence selectivity.

Conclusions:

  • Understanding anthracycline-DNA topoisomerase II interactions is vital for designing improved cancer drugs.
  • Structure-activity relationships guide the synthesis of analogues with better efficacy and reduced toxicity.
  • Advances in synthesis and drug delivery offer new therapeutic possibilities.